Positive preliminary results for Eli Lilly’s efsitora alfa continue to build the case for this once-weekly insulin in type 2 diabetes patients. Lilly is trying to catch up to Novo Nordisk’s once weekly insulin icodec, which is commercially available in several markets around the world but is not yet approved by the FDA. The post…
Max Schachter wanted to be close to his son Alex on his birthday, July 9, so he watched old videos of him. “It put a smile on my face to see him so happy,” Schachter said. Alex would have turned 21 that day, six years after he and 16 other children and staff at Marjory…
The Trump administration withdrew the order a day after a federal judge temporarily blocked it
Facing mounting losses, Walgreens announces the closure of 1,200 locations in the next three years
The hospital giant has started making plans to absorb possible lost volumes from upheaval in the insurance market late this year.
Every day, patients are making agonizing choices to skip medications due to cost, and the fallout is evident in worsening health and avoidable hospitalizations. Health systems are in a prime position to break this cycle by acting as advocates for their patients’ financial as well as physical well-being. The post When Cost Blocks Care: Why Medication…
In this episode, we’re joined by Dr. Piraye Yurttas Beim, founder and CEO of Celmatix, a women’s health biotech company. She discusses the funding the company recently received through the Sprint for Women’s Health program. The post MedCity FemFwd: How Celmatix is Using ARPA-H’s Sprint for Women’s Health Funding appeared first on MedCity News.
In October, Stanford University professor Jay Bhattacharya hosted a conference on the lessons of covid-19 in order “to do better in the next pandemic.” He invited scholars, journalists, and policy wonks who, like him, have criticized the U.S. management of the crisis as overly draconian. Bhattacharya also invited public health authorities who had considered his…
As federal vaccine policy changes, most (59%) adults do not expect to get a COVID-19 vaccine this fall, while four in 10 (40%) say that they will “definitely” or “probably” get the shot, a new KFF Tracking Poll on Health Information and Trust finds. The groups most likely to say they will “probably” or “definitely”…More
To truly expand CAR T access and prepare for the wave of new T cell-based therapies coming through the pipeline, we must find better ways to manage CRS and ICANS. The post For Many, CAR T is a Miracle Therapy – We Need to Get it to More Patients appeared first on MedCity News.